Immuron Ltd — Regulatory Filings 2011

Jul 25, 2011

==> picture [164 x 35] intentionally omitted <==

TRAVELAN[®] DISCOVERED TO AFFECT E. COLI ASSOCIATED WITH EUROPEAN FOOD POISONING

 Potential future use in food poisoning outbreaks

26 July 2011: Immuron Limited (ASX: IMC) using in vitro testing has demonstrated that Travelan binds strongly to E. coli O104 surface antigen. This form of E. coli is the sub-type shown to cause the most recent outbreak of food poisoning in Europe.

This finding suggests that Travelan could reduce the risk of infection in those exposed to the European E. coli outbreak strain as it does for other pathogenic varieties of E. coli .

“This result provides an opportunity for Travelan, with its proven safety profile, to be expanded from its current indications,” said Joe Baini, CEO of Immuron.

Contact

Joe Baini – Chief Executive Officer +61 3 8637 1107 joe@immuron.com

Rudi Michelson Monsoon Communications (03) 9620 3333 0411 402 737

About Immuron Limited

Immuron is a biopharmaceutical company focused on oral immunotherapy using dairy-derived polyclonal antibody products for humans. Immuron is a uniquely positioned biotechnology company with a versatile technology platform capable of generating a wide range of products with a high safety profile. This high safety profile makes it possible to complete pre-clinical studies relatively quickly and increases the prospect that the clinical development of Immuron’s products will be expedited. Immuron’s current products and product candidates target infectious diseases of the gastrointestinal tract, chronic diseases such as type II diabetes and fatty liver (NASH), and the prevention of influenza. Immuron has one product in the market, Travelan, for use in preventing travellers’ diarrhoea.

Immuron’s main scientific alliances are with Hadassah Medical Center (Israel) and the Universities of Melbourne and Monash (Australia).